please select
Partnering with E-commerce Platforms to Capture China's Big Health Market(圖)
AMS BioteQ (stock code: 6864-TW) officially signed a distributor contract for the mainland China region with VITAHOUSE PHARAC PTY CO., LIMITED on the 17th of this month. This is an important step for us to capture the China's big health market.
AMS BioteQ's Innovative Medical Device Officially Enters Japan, Obtains Taiwan's First Japanese Medical Device Permit(圖)
AMS BioteQ (Stock Code: 6864), a biotech company, announced on July 11 that its innovative medical device "SIPSIP Foam Wound Dressing" has successfully obtained the first-class medical device sales permit from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), officially entering the Japanese market.
Emerging from Darkness, Reclaiming Vitality(圖)
Cancer has always been a formidable disease, and the reason it is so feared is because it carries the threat of death, the patient's fear of the unknown cancer process, and the potential for disability, pain, and physical deformities. This is an extremely difficult marathon race for both the patient and their family, and it often has a huge impact on their quality of life and emotional well-being.
The Silent Killer: The Underestimated Threat of Pressure Ulcers(圖)
Many elderly individuals or patients often face mobility issues due to their medical conditions or prolonged use of medical devices, which lead to a loss of autonomy. This can result in muscle and joint degeneration and increase the risk of pressure injuries, commonly known as bedsores or pressure ulcers.
AMS BioteQ Enters Shanghai, Targets China's Health and Wellness Market(圖)
The National Pharmaceutical Trade Fair (PHARMCHINA) was grandly held in Shanghai, China, from May 15 to 17, 2024. It is a large-scale professional exhibition for health nutrition and wellness products in China.
AMS BioteQ Invited to Inaugural CPHI Japan 2024(圖)
CPHI Japan was held grandly from April 17 to 19 this year (2024).
Superbugs Onslaught: A Novel Paradigm in Wound Care(圖)
Emergence of superbugs results from bacteria developing resistance to antimicrobial agents, posing a significant health threat.
Kaohsiung Medical University and AMS BioteQ signed an MOU for talent cultivation, aiming to foster pharmaceutical research talents and promote industry-academia collaboration.(圖)
In pursuit of academic exchange, fostering industry-academia collaboration, and talent cultivation, the School of Pharmacy at Kaohsiung Medical University and AMS BioteQ recently signed a memorandum of understanding (MOU) to enhance industry-academia exchange, promote the development of the domestic biopharmaceutical industry, and lay the foundation for pharmaceutical research talent cultivation.
AMS BioteQ's International Expansion Facilitates Immediate Aid for Post-War Reconstruction in Ukraine.(圖)
The "Connecting with Ukraine" economic revitalization event, orchestrated by the Japan International Cooperation Agency (JICA), convened from February 15th to 17th, 2024. This gathering served as a platform uniting businesses, manufacturers, and research institutions from Japan and Ukraine, pooling their resources to aid in the post-war reconstruction endeavors of Ukraine.
AMS BioteQ Unveils Breakthrough in Dressing Innovation, Redefining Medical Materials(圖)
On January 18th, AMS BioteQ (TPE: 6864) announced the successful approval of its application for a novel invention patent in Taiwan titled “ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND” by the Intellectual Property Office of the Ministry of Economic Affairs, R.O.C.
AMS BioteQ has achieved significant progress in the global wound dressing market by successfully obtaining U.S. FDA approval.(圖)
AMS BioteQ (TPE: 6864) announced on 11th Dec. last year that its innovative medical care product, "SIPSIP Foam," the wound dressing made of its patented bioengineering technology ExtrO, has successfully obtained the registration number issued by the U.S. FDA.
AMS BioteQ Wound Dressing Approved, Expanding into Innovative Medical Care Market(圖)
AMS BioteQ (stock code: 6864), a leading biotechnology company, announced on the 21st that its innovative medical care material, "SIPSIP Foam Yuanzhang Cotton Wound Dressing," has successfully obtained approval from the Taiwan Food and Drug Administration (TFDA), with a medical device approval permit number.